OBJECTIVES: Surgeons at different institutions worldwide choose different types of operations for thymic tumours. It is not known whether these differences affect the outcomes of the patients.
INTRODUCTION
Thymic epithelial tumours (TETs) arise from the thymic epithelium and include thymomas and thymic carcinomas. The current understanding is that all TETs should be considered malignant [1] . Complete (R0) resection, tumour stage and histological classification have been shown to be independent predictive factors of long-term outcomes [2, 3] . Other concerns also exist such as the potential for multifocal thymic disease and the subsequent development of myasthenia gravis (MG). Therefore, the classic teaching has been to resect the thymic tumour together with the entire thymus gland and all involved structures [4] , and a median sternotomy has been accepted as the standard approach to accomplish these goals for reasons of safety and oncological concerns, because it offers satisfactory exposure of the anterior mediastinum and adjacent structures.
However, several recently published series have shown no difference in the completeness of resection, rate of MG development or overall survival in early stage TETs after either total or partial thymectomy [5, 6] , including a propensity score-matched study from the Japanese Association for Research on the Thymus [7] . These findings have called into question the need to resect the entire thymus gland during the surgical management of TETs. Interestingly, the studies favouring partial thymectomy were all carried out in Asia: in one of these studies, more than half of the partial thymectomies were performed via the lateral open approach [5] , whereas in the others, the partial thymectomies were done by video-assisted thoracoscopic surgery (VATS) [6] . Their results prompted us to initiate a geographical analysis to compare the surgical approaches and extent of resection for early stage thymic tumours in patients from different continents, in addition to a general study on the extent of the resection [8] .
MATERIALS AND METHODS

Patients
We queried the International Thymic Malignancy Interest Group retrospective database to access data from 2000 to 2014. In contrast to an earlier study from the same database comparing open and minimally invasive approaches to thymic resection [9] , the timing of this query included cases from the Chinese Alliance of Research in Thymomas institutions that were added to the database in December 2014. This additional cohort of cases resulted in a data set that had enough cases with sufficient follow-up duration and recurrence information to permit statistical analysis of longer term outcomes. Collection of follow-up data was the responsibility of each institution. Follow-up information was added when the database was closed in 2013, except for the additional cases from the Chinese Alliance of Research in Thymomas, which were added at the end of 2014. Ethics board approval was waived because only de-identified data was used for the study.
Patients with Masaoka-Koga pathological Stage I-II thymoma and thymic carcinoma were grouped as having primary total thymectomy (TT) or partial thymectomy (PT). A TT was defined as resection of the thymic tumour along with the entire thymus gland, whereas a PT was defined as resection of the thymoma with a margin of normal thymic tissue only. Patients with preoperative MG who received induction chemotherapy or radiation therapy, who had extended thymectomy and who did not have a World Health Organization histological classification were excluded. Two patients from South America were also excluded because they would not have constituted a separate geographic group. We had a final data set of 1430 cases for analysis. They were then divided into 3 geographic groups: Europe (EU), North America (NA) and Asia (AS).
An initial analysis of the baseline patient characteristics was performed to assess the potential differences between the groups and to ascertain whether a more sophisticated statistical analysis such as a propensity score-matched study or subgroup analysis was necessary. In addition, event rates of death and recurrence were determined. There were too few deaths or recurrences to permit a statistically valid propensity score-matched analysis or a stratified analysis. However, there were differences between the groups that led to univariable and multivariable analyses to assess the factors that might influence survival and recurrence.
To facilitate statistical analysis, patients whose tumours were approached through a clamshell (3) or sternotomy + thoracotomy (1) were included in the sternotomy (median open) group; those whose tumours were approached through a hemi-clamshell incision (11) 
Outcomes
Primary outcomes of the study included overall survival (OS) and cumulative incidence of recurrence (CIR) of TETs. Secondary outcomes included completeness of resection (R0, R1 and R2) and the use of adjuvant therapies.
Statistics
All analyses were performed using SAS 9.3 (SAS Institute Inc, Cary, NC, USA) and R version 3. The association of overall survival with clinical and prognostic factors was tested using the log-rank test. CIR was assessed using competing risk analysis, with death included as the competing event (curves of death are not shown in the cumulative incidence plot). The difference in recurrence-free survival among different continents was assessed using Gray's test [10] . In multivariable analysis, the Cox proportional hazards model was used for OS and the cause-specific hazard model was used for recurrence. A P-value of <0.05 was considered statistically significant.
RESULTS
A total of 1430 patients were identified, with 293 (20.5%) patients in EU, 298 (20.8%) in NA and 839 (58.7%) in AS. The demographic and tumour characteristics for the patients in each geographic group are found in Table 1 . Patients from the 3 continents were comparable in gender and performance status. EU patients had more paraneoplastic syndromes. NA patients had the smallest tumour sizes. AS patients were younger and had more Stage I disease but also had a larger percentage of highgrade tumours (type B3 thymoma and thymic carcinoma).
The extent of resection in 1141 (79.8%) patients was a TT and in 289 (20.2%) patients was a PT. A PT was performed significantly more often in patients from AS than in those from the EU or NA (31.7% vs 2.4% vs 5.4%, P < 0.001; Table 2 ). A median approach (sternotomy/clamshell) was used more frequently in EU and NA, whereas unilateral open (thoracotomy/hemi-clamshell) and minimally invasive approaches (VATS/robot) were used more often in AS. A time-trend analysis showed a rapid increase in minimally invasive approaches along with a resultant decrease in both median and unilateral open approaches in recent years (Fig. 1A) . Overall, PT was used in a steady frequency during the duration of the study (Fig. 1B) . Even after breaking down the groups by continent, no clear change in the frequency of PT was observed in the patients from any one continent (Fig. 1C) .
The complete resection (R0) rates were comparable between patients from AS and EU, but both were significantly higher than that for patients from NA (Table 2 ). However, most of the incomplete resections in NA were R1 (23/26) cases. R2 resection rates were similar among the geographic groups. Postoperatively, adjuvant chemotherapy was delivered most frequently to AS patients, whereas adjuvant radiation was used less frequently in NA patients. The infrequent use of adjuvant radiation in the NA group was seen in patients after complete and incomplete resections (Table 2 ). There was no significant difference in OS in patients with or without adjuvant chemotherapy (P = 0.45) or adjuvant radiation (P = 0.11).
On multivariable analysis, different continent (AS vs EU or NA), surgical approach (lateral open or minimally invasive vs median) and tumour size were identified as predictive factors for undertaking a TT (Table 3) . Median tumour size was largest in the lateral thoracotomy group (7 cm), followed by the median sternotomy group (6 cm), and was the smallest in the minimally invasive group (5 cm) (P < 0.001).
A total of 61 deaths were recorded at the conclusion of the study period, with 18 from AS, 19 from EU and 24 from NA. The 5-and 10-year OSs were 91% and 82% for EU, 91% and 78% for NA and 95% and 90% for AS ( Fig. 2 ; P = 0.005). Thirty-six recurrences were recorded: 14 from AS, 10 from EU and 12 from NA. However, recurrence rates were similar among the 3 geographic groups, with the 5-and 10-year CIR being 0.07 and 0.07 for NA, 0.03 and 0.08 for AS and 0.06 and 0.06 for EU ( Fig. 3 ; P = 0.61). Multivariable analysis looking at survival identified only age as an independent predictive factor for OS (P < 0.001, HR = 1.089, 95% CI 1.056-1.123; Table 4 ). Comparatively, only histologically high-grade tumours (types B3 and thymic carcinoma, P = 0.003, HR = 3.932, 95% CI 1.615-9.576) were shown to be independent risk factors for increased recurrence (Table 5) . Surgical approach, extent of resection or adjuvant therapies were not found to be related to OS or CIR. 
DISCUSSION
The major finding of this study is that surgeons from different continents have their preferred surgical approaches for early stage TET, both in the choice of incision and in the extent of resection. This difference is surprising because we believed that classic teaching and common practice comprised removing the entire thymus (TT) through a median sternotomy. Our results showed that most surgeons in EU and NA abide by this teaching; however, surgeons in AS prefer unilateral approaches (thoracotomy, hemi-clamshell, VATS or robot) and more commonly perform a PT. In other words, if surgery were carried out in AS or through a lateral approach, PT would more likely be the selected procedure. However, these differences seem to have little impact on survival or recurrence. When a median approach is used, most surgeons perform a TT, given the access, exposure and ease of assessing the entire anterior mediastinum. However, splitting the sternum causes significant trauma and is associated with increased postoperative morbidities compared with thoracotomy or thoracoscopic surgery [11] . Although a complete resection of TET (R0) is also feasible using a unilateral approach, it is technically more demanding to access the contralateral gland for a TT. In one of the first reports, Blalock [12] reported using a partial sternotomy with a trap-door to do a partial thymectomy for a cystic thymoma. Wilkins et al. [13] also reported using PT in 11% of their cases, primarily through a thoracotomy. Sometimes a lateral approach may offer improved exposure, particularly at the lateral margin of a large, predominantly unilaterally located tumour when dissecting along the phrenic nerve. This observation is supported by our finding that median tumour size was largest (7 cm) in the thoracotomy/hemi-clamshell group and significantly larger than in the median sternotomy/clamshell group (6 cm, P = 0.004). There is increasing interest in minimally invasive resection for early stage thymic tumours (Fig. 1A) [14, 15] . Recent reports have also demonstrated that these minimally invasive approaches are being used for larger and larger tumours [16] . However, it seems that these approaches are more common in AS. Firstly, Asian surgeons are already accustomed to the unilateral open approach, which makes it easier to adapt to VATS thymectomy. Secondly, the concern about the morbidity of a sternotomy may be greater in AS, hence the desire to perform a unilateral, partial resection [5] . Lastly, some Asian surgeons believe that the low risk of recurrence or development of MG justifies a partial resection [5, 6] .
In this study, both unilateral open and minimally invasive approaches were inversely associated with TT. Overall, the proportion of PT to TT remained similar throughout the study period (Fig. 1B) . As a result, there was a concomitant decrease in the number of thoracotomies and an increase in minimally invasive surgery-both unilateral approaches. The technical difficulties may limit the endeavour for TT during thoracotomy, but it is hard to explain the higher percentage of PT in VATS/robotic cases since minimally invasive approaches allow for both TT and PT [14, 15] even with large tumours [16] . It is possible that some surgeons are willing to accept PT in early stage tumours, balancing between reduced surgical risk and the extremely low potential for recurrence, especially in an older individual.
For TETs, complete R0 resection remains a key prognostic factor [2, 3] , which would be an argument for TT. Although PT through a unilateral approach was used more often in AS, the R0 resection rate and long-term outcomes (10-year OS and CIR) were not inferior to those in the other 2 geographic groups. It is intriguing that R0 resection in NA was significantly lower than that in EU and AS. Technically it is not difficult to remove a Stage I or II TET completely, but a significant difference in resection status existed in both Stage I and II tumours (data not shown), with NA reporting an R1 resection in 23 of 26 cases. We suspect that surgeons or pathologists in NA are more cautious in confirming an R0 resection when the lesion closely abuts neighbouring structures during the operation or extends to the edge of the resected specimen on histological examination.
Another difference revealed by this study was the preference for adjuvant therapies in different regions. Adjuvant chemotherapy was used more frequently in AS, probably because of more high-grade tumours, especially thymic carcinomas, in the AS group. On the other hand, adjuvant radiation was used significantly more often in AS and EU than in NA, after both R0 and R1-2 resections. This result could only be explained by different attitudes towards adjuvant radiation among medical personnel from the 3 continents. Given that the study population had early stage tumours, it is not surprising that neither chemotherapy nor radiation turned out to be a predictive factor for survival or recurrence in multivariable analysis. The role of adjuvant therapies needs to be verified in future studies.
In this study, overall survival appeared to be higher in AS than in EU or NA. Although the higher percentage of Stage I disease in AS could be a favourable factor for better outcome, there was a higher proportion of high-grade tumours in this group, which might have offset the prognostic benefit of stage difference. In multivariable analysis for OS, only age turned out to be an independent predictive factor. Therefore, we assume that the difference in OS should be attributed more to patient characteristics (younger age in the AS group) than to oncological factors. Moreover, we found no significant difference in recurrence among the 3 groups. For indolent malignancies like TET, especially for early stage lesions, recurrence status probably is a better measure of outcome than survival [17] . Only high grade tumor histology was predictive of increased risk of recurrence in our study. These results demonstrate that the differences in surgical approach and the extent of resection had little impact on outcome. Although unilateral rather than median approaches and PT instead of TT were more often adopted in AS, with similar complete resection rates, OS and CIR in the AS group were at least not inferior to the results from the other 2 continents.
This study has several limitations. Pathological instead of clinical stage was used as an inclusion criterion. In practice, surgical approach and the extent of resection are decided beforehand, whereas pathological staging is determined after the operation based on a histological examination. We attempted an analysis by clinical stage but found a high proportion of cases with missing data, making the validity of the analysis questionable. Also, the fact that follow-up for VATS/robotic cases tended to be shorter, because minimally invasive thymic surgery became popular only recently, may be a limiting factor in interpreting our results. However, lateral approaches and PT remained at a steady rate throughout the study. Therefore, differences in follow-up time would have little impact on the analysis of approach or the extent of resection as our end-points.
In conclusion, we observed a significant difference in surgical approach and the extent of resection for non-MG, MasaokaKoga pathological Stage I and II thymic tumours among patients from EU, NA and AS. Despite these differences, we noted little difference in resection rate and recurrence status. For early stage thymic tumours with a high rate of complete resection, longterm overall survival depended mainly on the patient's age, and the risk of recurrence was associated with the histological characteristics of the tumour. Together these findings suggest that we should be more willing to consider different approaches and the extent of resection for well circumscribed small, anterior mediastinal lesions presumed to be a thymoma, provided that an R0 resection can be achieved.
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APPENDIX. CONFERENCE DISCUSSION
Dr F. Venuta (Rome, Italy): I have 3 questions for you. You have considered the presence of myasthenia gravis to be an exclusion criterion for this study. However, you mentioned that there were other paraneoplastic syndromes that were considered in this population with some geographical differences. What were these paraneoplastic syndromes that you did not consider to be contraindications for inclusion in this study? And for these syndromes (since complete thymectomy should be considered also for them as well as for myasthenia gravis) what was the outcome and was it possible to compare outcome according to partial or total thymectomy for these syndromes?
The second question concerns adjuvant therapy. Did you investigate whether there was any statistically significant difference in the group of patients undergoing partial thymectomy between those receiving or not adjuvant therapy?
Then concerning the recurrence rate, you mentioned that this was similar in the 3 geographical areas. However, did you investigate whether there was any difference in the Asian population between the group undergoing partial and total thymectomy and between those receiving or not adjuvant treatment?
Dr Fang: In response to the first question, we deliberately excluded patients with myasthenia gravis, as you mentioned, because in these patients total thymectomy would inevitably have been the choice of procedure. However, we did include some other para-neoplastic syndromes, such as para-carcinoid syndromes, but not those autoimmune diseases. So I do not think total thymectomy would be an impacting factor in this case.
Regarding the second question, we did investigate the role of adjuvant radiation and chemotherapy and their relationship to and impact on survival or recurrence, but we found no difference in both univariate and multivariate analyses.
As for the third question, well, it is a tough one, because we did a similar study using the Chinese database, and we found a little difference in the recurrent status in Chinese patients between total and partial thymectomy. But I think that the difference in the results might be related to the different duration of follow-up on patients. As you can see from the results of this study, the follow-up for VATS and robotic surgery patients is quite short compared to other subgroups of patients. So I think this might be due to the difference in the follow-up duration. That is why we suggested that future studies would be necessary with an increasing number of patients as well as prolonged follow-up, so as to reach a more definite conclusion. Dr E. Lim (London, UK): This is a big series of resection for thymic tumours. I am particularly interested in the recurrence rate with partial resection. I think it is probably the most important statement in your article. Can I ask you 1 or 2 questions. The first question is, what do you think represents an important difference in recurrence rate in terms of percentage: 10, 20? What would your impression be?
Dr Fang: It is very low. We had very few events in this series of patients, probably because they are all early stage diseases. In fact, we wanted to do a propensity score matched study for the risk factors, but our statisticians advised against it because there were too few events.
Dr Lim: So my question relates to that. If you consider a 20% difference an important difference in recurrence rate between total and partial thymectomies, your hazard ratio for recurrence is 1.68, implying a 70% increase in recurrence with partial thymectomy.
Dr Fang: I didn't quite catch your question. Sorry. Dr Lim: The hazard ratio reported for recurrence rate for partial thymectomy in your presentation was 1.68. It was not statistically significant. It implied a 70% increase in recurrence in partial thymectomies. The results were not significant because the numbers were small and the number of events was also correspondingly very small. So what I am implying is, do you think that this study is underpowered? Dr Fang: Because the patients we included in this study were those with early stage tumours, it is not surprising that the recurrence rate is extremely low and there are too few events for a robust statistical analysis to reach a significant difference statistically. However, this is the largest multi-institutional and multi-continental data we have attained, and I don't think there is a possibility to have even more cases for that. This question could only be solved in the future by a prospective analysis. ITMIG is doing this Global Asset procedure to prospectively include patients from all participating centres worldwide. This would allow us a more realistic approach to solve the problems related to thymic tumours.
Mr D. Waller (Leicester, UK): We are now starting to understand thymic cancer a bit more with your excellent work from ITMIG. We seem to have forgotten one of the basic oncological principles in thymic tumours or any cancers of the chest, and that is lymph node dissection, and you are quoting R0 resections without any evidence of any lymph node sampling or dissection. Can you comment on that?
Of course, one of the major criticisms of minimally invasive lung cancer surgery was the ability to obtain a comparative lymph node dissection. Do you have any data from your database or could you hypothesize whether you could do such an adequate lymph node dissection from a unilateral video-assisted approach compared to a median sternotomy approach?
Dr Fang: I think it is an excellent question, as lymph node dissection has never been paid enough attention in thymic surgery. Also, I would like to tell you that we have been using a Chinese database to do a retrospective study on lymph node status and its impact on survival; I think Dr Gu will give this talk later at this meeting. But the preliminary results show that the lymph node metastases rate for thymic tumours is extremely low, especially for thymomas, where it is less than 3%, and only in a small, special group such as thymic carcinoids might it reach as high as a 2-digit level.
Technically I think it is feasible to dissect the lymph nodes, especially the anterior mediastinal lymph nodes, through minimally invasive approaches, and there are surgeons using subxiphoid bilateral approaches for thymic tumours as well. So it is not a technical difficulty, but the philosophy of the surgeon in managing the disease. I think a prospective study is also needed.
